Search results
Results from the WOW.Com Content Network
As of November 2015, there are a number of ongoing and recently completed clinical trials of novel targeted agents for HER2+ metastatic breast cancer, e.g. margetuximab. [36] Additionally, NeuVax (Galena Biopharma) is a peptide-based immunotherapy that directs "killer" T cells to target and destroy cancer cells that express HER2. It has entered ...
Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification (i.e. the tumor is negative on all three tests giving the name triple-negative). [1]
Metastatic breast cancer to the lung or pleura causes chronic cough, dyspnea, abnormal chest X-ray, and chest pain. Other nonspecific systemic symptoms of metastatic breast cancer include fatigue, malaise, weight loss, and poor appetite. Sometimes people with metastatic breast cancer do not have any notable changes or symptoms. [8]
This is an accepted version of this page This is the latest accepted revision, reviewed on 30 December 2024. Cancer that originates in mammary glands Medical condition Breast cancer An illustration of breast cancer Specialty Oncology Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on the ...
Metastatic lesions from breast cancer may produce symptoms according to that organ system. The most common sites for metastasis are the bone, lung, liver, and brain. [17] Skin metastases most commonly extend to the skin overlying the mass, but may spread to the axilla or more distant areas. [18]
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
The estrogen and progesterone receptors and HER2/neu protein, when expressed by breast cancer tumor cells, are therapeutic targets for treating various forms of breast cancer including ICCB. [ 13 ] [ 14 ] ICCB tumors also typically have cells that express cytokeratin proteins but not myoepithelial marker proteins such as tumor protein 63 ...
ER-positive is one of the Receptor statuses identified in the classification of breast cancer.Receptor status was traditionally considered by reviewing each individual receptor (ER, PR, her2) in turn, but newer approaches look at these together, along with the tumor grade, to categorize breast cancer into several conceptual molecular classes [1] that have different prognoses [2] and may have ...